NCT03403725View on ClinicalTrials.gov

MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study

PHASE1TerminatedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 28, 2017

Primary Completion Date

October 22, 2019

Study Completion Date

January 8, 2020

Conditions
Metastatic Solid TumorsRelapsed/Refractory Non-Hodgkin Lymphoma
Interventions
DRUG

MEN1309

MEN1309 solution for intravenous infusion once every 3 weeks

Trial Locations (7)

4000

CHU Sart Tilman, Liège

20132

IRCCS Ospedale San Raffaele, Milan

28040

START Madrid. Fundacion Jimenez Diaz, Madrid

28050

Centro Integral Oncologico Clara Campal, Madrid

33081

Centro Riferimento Oncologico, Aviano

Unknown

Vall d'Hebron Barcelona Hospital, Barcelona

NE7 7DN

NCCC Clinical Trials Pharmacy, Northern Centre for Cancer Care, Newcastle upon Tyne

Sponsors

Lead Sponsor

Menarini Group
All Listed Sponsors
lead

Menarini Group

INDUSTRY